SG/CALL/ELI LILLY & CO/950/0.1/20.09.24 | Market Closed - Börse Stuttgart 08:22:36 09/05/2024 BST | ||
| 1.3 EUR | -6.47% |
|
| Current month | +9.24% | ||
| 1 month | -43.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/05/24 | 1.3 | -6.47% | 0 |
| 08/05/24 | 1.39 | +19.83% | 0 |
| 07/05/24 | 1.16 | +34.88% | 0 |
| 06/05/24 | 0.86 | -14.00% | 0 |
| 03/05/24 | 1 | -32.43% | 0 |
Delayed Quote Börse Stuttgart
Last update May 09, 2024 at 08:22 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU92XZ |
| ISIN | DE000SU92XZ1 |
| Date issued | 29/02/2024 |
| Strike | 950 $ |
| Maturity | 20/09/2024 (134 Days) |
| Parity | 10 : 1 |
| Emission price | 2.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.14 € |
|---|---|
| Lowest since issue | 0.86 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
775
USD
Average target price
850.4
USD
Spread / Average Target
+9.73%
- Stock Market
- Warrants
- Warrant
